The telomere-capping complex shelterin protects functional telomeres and prevents the initiation of unwanted DNA-damageresponse pathways. At the end of cellular replicative lifespan, uncapped telomeres lose this protective mechanism and DNAdamage signalling pathways are triggered that activate p53 and thereby induce replicative senescence. Here, we identify a signalling pathway involving p53, Siah1 (a p53-inducible E3 ubiquitin ligase) and TRF2 (telomere repeat binding factor 2; a component of the shelterin complex). Endogenous Siah1 and TRF2 were upregulated and downregulated, respectively, during replicative senescence with activated p53. Experimental manipulation of p53 expression demonstrated that p53 induces Siah1 and represses TRF2 protein levels. The p53-dependent ubiquitylation and proteasomal degradation of TRF2 are attributed to the E3 ligase activity of Siah1. Knockdown of Siah1 stabilized TRF2 and delayed the onset of cellular replicative senescence, suggesting a role for Siah1 and TRF2 in p53-regulated senescence. This study reveals that p53, a downstream effector of telomere-initiated damage signalling, also functions upstream of the shelterin complex.
In response to DNA damage, and other stresses, the tumour suppressor protein p53 initiates cellular senescence, which functions as a tumour suppressor mechanism in vivo, and may also be involved in organismal ageing 1, 2 . p53 may partly influence both ageing and carcinogenesis by regulating self-renewal, genome stability and differentiation of normal and cancer stem cells [3] [4] [5] . Uncapped or dysfunctional telomeres, which are associated with the end stage of the replicative lifespan of normal human cells, are an endogenous DNA damage that activates p53 to induce cellular senescence 2, [6] [7] [8] . Telomere dysfunction also impairs the functional integrity of adult-tissue stem cells 3, 9, 10 and inhibits the reprogramming of differentiated cells into induced pluripotent stem (iPS) cells 11 . The telomere-capping protein-complex shelterin contains singlestranded-and double-stranded-telomere-binding proteins (including TRF2) 12 , and forms and maintains the structure of functional telomeres, inhibiting unwanted DNA-damage responses at chromosome ends 13 . Specifically, TRF2 is responsible for the formation and maintenance of 't-loop' structure 14 , and prevents ATM kinase from activating downstream factors, including p53, that would trigger DNA-damage responses that lead to cellular senescence 15 . As such, experimental inhibition of TRF2 induces cellular senescence through the ATM-and p53-mediated pathway 8, 12, 16, 17 . A recent report indicated that TRF2 also inhibits another kinase in this pathway, Chk2, which is phosphorylated by ATM and phosphorylates p53 (ref. 18 ). These findings have established p53 as a downstream effector of DNA-damage signalling from uncapped, dysfunctional telomeres. However, it is unknown whether p53 also functions upstream to regulate a structural and/or functional component of the telomere-capping complex or the telomere DNA-damage-response machinery. This study reveals proteolytic regulation of TRF2 by p53 through a p53-inducible E3 ubiquitin ligase, and provides insight into the telomere-damage signalling mediated by p53 during cellular senescence, with significant implications for carcinogenesis, ageing and stem cell biology.
RESULTS

Downregulation of TRF2 and upregulation of Siah1 during replicative senescence
The endogenous expression of TRF2 protein (detected as approximately 65-and 69-K doublet bands in an immunoblot, as previously reported 19, 20 ) was reduced when human fibroblast strains (MRC-5 and WI-38) underwent replicative senescence (Fig. 1a) . Replicative senescence was induced by DNA damage at critically shortened, uncapped telomeres ( Supplementary Information, Fig. S1 ) 8, 21, 22 . The reduction of TRF2 during replicative senescence was confirmed by immunofluorescence microscopy ( Supplementary Information, Fig. S2a ), but there was no change in TRF2 mRNA level (Fig. 1b) , suggesting post-transcriptional regulation. The senescent state of these cells was associated with the activation of the p53 signalling pathway, as revealed by the increase in the phosphorylation of p53 at Ser 15 and the upregulation of p21 WAF1 , whereas total amounts of p53 did not significantly change (Fig. 1a ) 23 . Siah1, an E3 ubiquitin ligase known to be transcriptionally induced by p53 (refs 24, 25) , was upregulated during replicative senescence (Fig. 1a) . Although endogenous Siah1 was readily detectable when we used either nuclear extracts (Fig. 1a) or total protein lysates (Fig. 2a , for example) in the immunoblot analysis, the former generally gave higher sensitivity of detection, probably from nuclear enrichment of Siah1 protein ( Supplementary Information, Fig. S3a ). In the data shown hereafter nuclear extracts were used, whenever available, for detecting Siah1 protein. The upregulation of Siah1 during replicative senescence was confirmed to occur at the mRNA level (Fig. 1c) .
When three other shelterin components (RAP1, POT1 and TPP1) were examined by immunoblot, RAP1 was slightly decreased and POT1 and TPP1 were increased during replicative senescence ( Supplementary  Information, Fig. S4a ), suggesting that senescence-associated downregulation is not common to all shelterin components.
p53 induces Siah1 and represses TRF2
In a fibroblast strain derived from a Li-Fraumeni syndrome patient, the loss of wild-type p53 alleles increased TRF2 expression (Fig. 2a) . The short hairpin RNA (shRNA) knockdown of endogenous p53 in human fibroblasts resulted in an increased amount of TRF2 protein, as detected by immunoblotting (Fig. 2b ) and immunofluorescence microscopy ( Supplementary Information, Fig. S2b ), which again was not because of a change in TRF2 mRNA level (Fig. 2c) . The stabilization and activation of endogenous p53 by a small-molecule inhibitor of MDM2 (Nutlin-3a) resulted in a p53-dependent decrease in TRF2 expression (Fig. 2d) . In these experiments, the expression of Siah1 protein was inversely correlated with the expression of TRF2 protein; Siah1 was decreased when TRF2 was increased (through loss or knockdown of p53; Fig. 2a, b) , and Siah1 was increased when TRF2 was decreased (with Nutlin-3a activation of p53; Fig. 2d ). Decreased SIAH1 mRNA levels were also confirmed in cells with p53 knockdown (Fig. 2e) . In contrast, the expression of the other Siah family protein, Siah2, did not depend on p53 and did not show an inverse correlation with TRF2 expression (Fig. 2b) . These results suggest that p53 transcriptionally induces Siah1 and post-transcriptionally represses TRF2.
The p53 regulation of Siah1 and TRF2 was further substantiated by an additional set of experimental manipulations of p53 expression and activity. The overexpression of wild-type p53 led to increased Siah1 and decreased TRF2 ( Supplementary Information, Fig. S5a ). The overexpression of a dominant-negative isoform of p53 (Δ133p53; refs 23, 26) led to decreased Siah1 and increased TRF2 in human fibroblasts ( Supplementary Information, Fig. S5b ). In p53-deficient 293T cells, expression of Δ133p53 had no effect on TRF2 protein levels by itself, but abrogated the wild-type p53-induced downregulation of TRF2 ( Supplementary Information, Fig. S5c ). Consistently, small interfering RNA (siRNA)-mediated knockdown of endogenous Δ133p53 (ref. 23) resulted in increased Siah1 and decreased TRF2 in human fibroblasts ( Supplementary Information, Fig. S5d ).
Inhibition of Siah1 stabilizes TRF2 protein
To examine whether endogenous Siah1 regulates TRF2 protein levels, siRNA-mediated knockdown of Siah1 was performed. Two independent siRNA oligonucleotides resulted in increased amounts of TRF2, indicating a correlation between Siah1 knockdown efficiency and TRF2 increase (Fig. 3a) . The inhibition of protein synthesis by cycloheximide, followed by immunoblotting at different time points, indicated that Siah1 knockdown (using siRNA 2, which had higher knockdown efficiency) markedly extended the half-life of TRF2 protein (≥ 8 h, compared with < 4 h in the control; Fig. 3b, c) . These results suggest that endogenous Siah1 functions to limit TRF2 protein levels. The expression of any of the other shelterin components (RAP1, POT1 and TPP1) was not altered by Siah1 knockdown ( Supplementary Information, Fig. S4b ), which suggests that there is a specific regulation of TRF2 by Siah1.
Inhibition of endogenous Siah1 activity by the overexpression of a dominant-negative Siah1 mutant lacking the RING finger domain (FlagSiah1 , p53 phosphorylated at serine 15 (pS15-p53) and Siah1 were examined by immunoblot in early-passage (Y) and senescent (S) human fibroblast strains MRC-5 and WI-38. The examined passage numbers were 30 (Y) and 65 (S) for MRC-5; and 30 (Y) and 58 (S) for WI-38. β-actin and histone H2B were loading controls. The top three panels used total protein lysates and the bottom three panels used nuclear extracts (NE). Three independent experiments gave reproducible results. (b) TRF2 mRNA levels are not changed during replicative senescence. The same set of cells as in a were examined for TRF2 mRNA expression by real-time quantitative reverse-transcriptase PCR (qRT-PCR). β2-microglobulin mRNA expression was used as a control. Data are means ± s.d. from three independent experiments. (c) SIAH1 mRNA levels are increased during replicative senescence. The same set of cells as in a and b were examined for SIAH1 mRNA expression by qRT-PCR. β2-microglobulin mRNA expression was used as a control. Data are mean ± s.d. from three independent experiments. Asterisk indicates P < 0.01. Uncropped images of blots are shown in Supplementary Information, Fig. S9 .
Information, Fig. S5e ). Overexpression of a stabilized form of Siah1 (Flag-Siah1-Δ6) 25 , similar to that of p53, resulted in the downregulation of TRF2 ( Supplementary Information, Fig. S5f ). These results provide additional support for the Siah1-mediated downregulation of TRF2 protein.
TRF2 is subject to proteasomal-mediated degradation and is ubiquitylated in a p53-and Siah1-dependent manner When human fibroblasts (MRC-5) were treated with proteasome inhibitor MG132, TRF2 protein levels were significantly increased, both at early passage and at replicative senescence (Fig. 4a) . p53 levels are regulated through proteasomal-mediated degradation 28 , and so as expected, p53 levels also increased on MG132 treatment (Fig. 4a) . Similar results were obtained using WI-38 fibroblasts (data not shown). Thus, increased p53 was not coincident with decreased TRF2 when proteasomal-mediated degradation was blocked. In hTERT-immortalized fibroblasts (hTERT/ NHF), proteasome inhibition by MG132, and inhibition of p53 activity by expression of Δ133p53 or shRNA knockdown, resulted in similar increases in the levels of TRF2 protein (Fig. 4b) . In p53-inhibited cells, MG132 treatment did not lead to an additional increase in TRF2 (Fig. 4b) . These findings suggest that TRF2 is degraded through a proteasome-mediated mechanism that is activated by p53 and enhanced as cells approach replicative senescence.
Immunoprecipitation with anti-TRF2 antibody and subsequent immunoblotting with anti-polyubiquitin antibody indicated that TRF2 itself and/ or its interacting protein(s) were polyubiquitylated in vivo in human fibroblasts (Fig. 4c, d ). To examine whether endogenous amounts of Siah1 and p53 are involved in the TRF2-associated polyubiquitylation in vivo, endogenous Siah1 or p53 were knocked down and an immunoprecipitationimmunoblot experiment was performed (Fig. 4d) . The knockdown of Siah1 resulted in an approximately 50% decrease in the polyubiquitylation signals. The knockdown of p53 also abrogated polyubiquitylation, as shown by an approximately 70% decrease in the smear signals. In a p53-proficient colon cancer cell line, RKO, the dominant-negative inhibition of endogenous Siah1 activity (by expression of Flag-Siah1 ΔRING ) 27 reduced TRF2-associated polyubiquitylation by approximately 50% ( Supplementary Information,  Fig. S6a ). Doxorubicin treatment enhanced polyubiquitylation, probably through DNA-damage-induced p53 activation. The effect of doxorubicin treatment was abrogated by the dominant-negative inhibition of endogenous Siah1 ( Supplementary Information, Fig. S6a ). These data suggest that endogenous p53 and Siah1 positively regulate in vivo ubiquitylation of TRF2 and/or its interacting protein(s).
Siah1 ubiquitylates TRF2 in vitro and in vivo
These data, as well as the presence in TRF2 of a Myb DNA-binding domain 12 that is known to be targeted by Siah1 for protein degradation , was able to produce the smear signal derived from GST-TRF2, but not from GST alone (Fig. 5b) . The complete dependence of this signal on the intact RING finger domain of Siah1, the presence of TRF2 polypeptide sequences in the substrate, and the inclusion of ubiquitin in the assay (Fig. 5b) , confirmed that this in vitro assay specifically detected the ability of the Siah1 E3 ubiquitin ligase to add polyubiquitin chains to TRF2. We thus conclude that Siah1 interacts with, and ubiquitylates, TRF2 in vitro. Mass spectrometry analysis identified the lysine residue at amino acid position 173 as the major ubiquitylation site of TRF2, with a concomitant ubiquitylation of lysine residue at either position 180 or 184 ( Supplementary  Information, Fig. S8 ).
To further examine whether Siah1 is the E3 ligase responsible for TRF2 ubiquitylation in vivo, a transient expression-based assay was performed, in which exogenously expressed p53, TRF2 (Myc-tagged) and ubiquitin (HA-tagged) induced de novo TRF2 ubiquitylation detected by anti-Myc antibody or anti-HA antibody in p53-deficient 293T cells (Fig. 5c ). The inhibition of endogenous Siah1 by pre-treatment with the siRNA oligonucleotides almost completely abrogated the p53-dependent signals detected by anti-Myc antibody (corresponding to the ubiquitylation of Myc-tagged TRF2 alone) and by anti-HA antibody (probably including the ubiquitylation of the interacting proteins, such as auto-ubiquitylated Siah1; ref. 30 , Fig. 5c ). This finding indicates that Siah1 is essential to p53-induced TRF2 ubiquitylation in vivo, consistent with its in vitro catalytic activity on TRF2.
Siah1 and TRF2 regulate cellular replicative lifespan in vitro and are associated with cellular senescence in vivo Overexpressed TRF2 was previously shown to delay the onset of replicative senescence 31 . To investigate the roles of endogenously expressed Siah1 and TRF2 in the regulation of replicative senescence, MRC-5 human fibroblasts approaching replicative senescence were transfected with siRNA against Siah1 or control siRNA every 4 days and the replicative lifespan of the cells was determined as cumulative population doubling levels (PDL; Fig. 6a ). The knockdown of endogenous Siah1 by transfection of cells with two independent SIAH1 siRNA oligonucleotides, and the resulting increase in endogenous TRF2, were confirmed when the cells were growing (at day 20) and when they were growth-arrested (at day 88; Fig. 6b ). The Siah1 knockdown cells had increased proliferation rate in the early phase of the experiment and had an extended replicative lifespan, which was approximately 2 or 3 PDL longer than control cells (Fig. 6a ). This is consistent with our previous finding that Δ133p53 overexpression, which downregulated endogenous Siah1 and upregulated endogenous TRF2 ( Supplementary  Information, Fig. S5b ), resulted in accelerated cell proliferation and extended replicative lifespan in human fibroblasts 23 . However, whereas the dominant-negative inhibition of p53 by overexpression of Δ133p53 led to the repression of p21 WAF1 , as previously described 23 , the Siah1 knockdown cells had increased levels of p21 WAF1 , with a slight increase in p53, even when they were proliferating (Fig. 6b) . Therefore, our data demonstrate that endogenously expressed Siah1 and TRF2, as the downstream effectors in a p53 signalling pathway, contribute to the regulation of replicative senescence. Furthermore, our data suggest that elevated levels of endogenous TRF2 function to extend cellular replicative lifespan either in cooperation with the repression of p21 WAF1 by p53 inhibition 23 or in a manner that is resistant to increased p21 WAF1 (Fig. 6a, b) . The Siah1 knockdown cells eventually ceased proliferation with marked induction of p16 INK4A (Fig. 6b) , the other major effector of cellular senescence in human cells 32, 33 . Notably, the TRF2 upregulation-associated extension of replicative lifespan irrespective of p21 WAF1 expression is in contrast to the TRF2 inhibition-induced cellular senescence through p53-p21 WAF1 signalling 16, 17 . Evidence that the p53-and Siah1-mediated downregulation of TRF2 occurs in vivo was obtained from the analysis of human colon adenoma tissues, a pre-malignant tumour associated with p53-mediated cellular senescence 23, 34 . The eight cases of colon adenoma examined were previously confirmed to show senescent phenotypes, including senescenceassociated β-galactosidase activity and increased expression of p16 and interleukin-8 (IL-8; ref. 23). TRF2 expression was downregulated in all of these adenoma tissues, compared with adjacent non-adenoma tissues ( Fig. 6c and Supplementary Information, Fig. S5g ). Consistent with our in vitro data, adenoma tissues expressed higher amounts of Siah1, at a statistically significant level (Fig. 6d) .
DISCUSSION
This study reveals a novel molecular mechanism for the regulation of TRF2 that involves the tumour suppressor p53 and the p53-induced E3 ubiquitin ligase Siah1. Significantly, p53 is not only activated by DNA-damage-signalling from uncapped telomeres [6] [7] [8] , but also in turn controls an essential component of the telomere-capping protein complex, TRF2. We thus propose that the p53-Siah1-TRF2 pathway has an integral function in controlling the telomere-initiated DNA-damage response. As loss or functional inhibition of TRF2 at uncapped telomeres allows ATM to initiate DNA-damage signalling and activate downstream effectors, such as p53 (refs 15-17) , a feedback regulatory loop involving TRF2, ATM and p53 functions to amplify telomere dysfunction-induced, p53-mediated cellular responses. Activated p53 results in, through Siah1-mediated ubiquitylation and degradation, further inhibition of TRF2, which in turn leads to further enhanced activity of p53. The TRF2-ATM-p53 positive feedback loop may also cooperate with negative-feedback loops, involving p53, MDM2, Wip1 and ATM, to generate sustained oscillations in p53 activity 35, 36 . The ATM-dependent phosphorylation of Siah1 leads to disruption of the complex between Siah1 and its target HIPK2 (ref. 37) . It remains to be examined whether the phosphorylation of Siah1 adds a further complexity to the TRF2-ATM-p53 feedback regulation.
Although both TRF2 and Siah1 are localized mainly in the nucleus ( Supplementary Information, Fig. S3a ), ubiquitylated TRF2 was found mostly in the cytoplasm ( Supplementary Information, Fig. S3b ). This is not surprising because some proteins localized mainly in the nucleus, such as p27 Kip1 (ref. 38) and cyclin D1 (ref. 39) , are found to be ubiquitylated in the cytoplasm. The nuclear-cytoplasmic shuttling of β-catenin, another target of Siah1 for ubiquitylation and degradation, has an important role in the regulation of its turnover 40, 41 . It should be noted that, although total and nuclear TRF2 amounts were markedly decreased in replicatively senescent cells (Fig. 1a and Supplementary Information, Fig. S3a ), cytoplasmic TRF2 After extensive washing, the beads were boiled in SDS (sodium dodecyl sulfate) sample buffer and the eluted proteins were analysed by immunoblot using anti-GST and anti-TRF2 antibodies. In lanes 1, 7 and 8, His 6 -TRF2, GST-Siah1 and GST alone were run directly as input controls. A molecular weight marker was in lane 6 (MW). (b) Siah1 ubiquitylates TRF2 in vitro in a RING finger-dependent manner. Rabbit reticulocyte lysates (RRL), ubiquitin, an E3 ubiquitin ligase (wild-type Siah1, Siah1 H59W or Siah1 ΔRING ) and a substrate (GST or GST-TRF2) were added to an in vitro ubiquitylation reaction as indicated. After reaction, glutathione-Sepharose 4FF-purified substrates were analysed by immunoblot with anti-GST antibody. The position of non-ubiquitylated GST-TRF2 is indicated. Poly-ubiquitylated GST-TRF2 showed a smear signal (bracket) with the disappearance of non-ubiquitylated GST-TRF2. The experiment was repeated twice with reproducible results.
(c) Siah1 is essential to TRF2 ubiquitylation in vivo. Myc-tagged TRF2, HA-tagged ubiquitin (HA-Ub) and full-length p53 were transiently expressed in 293T cells, as indicated, which were pre-treated with control siRNA (-) or two different SIAH1 siRNA (indicated as 1 and 2). After treatment with MG132, protein lysates were prepared, immunoprecipitated with anti-Myc antibody or control IgG, and then analysed by immunoblot using anti-Myc antibody (top) and anti-HA antibody (bottom). The knockdown of Siah1 protein expression by SIAH1 siRNA was confirmed by immunoblot using total protein lysates before immunoprecipitation. β-actin was a loading control. White brackets indicate smear signals indicative of poly-ubiquitylation. The strong signals at the bottom of the top image correspond to IgG heavy chains. In the lower image, asterisks indicate non-specific bands. The closed arrowhead corresponded to the frontline of the electrophoresis, which probably contained non-specific signals and TRF2-associated ubiquitylated proteins of smaller size. The open arrowhead indicates a ubiquitylated protein of currently unknown origin. The experiment was repeated twice with reproducible results. Uncropped images of blots are shown in Supplementary  Information, Fig. S9 . levels were increased in these senescent cells ( Supplementary Information,  Fig. S3a) . Thus, the dynamic regulation of subcellular localization of TRF2 may be coupled with its Siah1-directed ubiquitylation and degradation. It remains to be examined whether p53 also regulates a factor that facilitates the nuclear-cytoplasmic shuttling of TRF2.
Although this study mostly used human fibroblasts, the p53-Siah1-TRF2 pathway seems to function in other cell types as well. DNA damage by doxorubicin treatment induced Siah1-mediated ubiquitylation of TRF2 in RKO colon cancer cells ( Supplementary Information, Fig. S6a ). Doxorubicin treatment resulted in p53-dependent reduction of TRF2 in HCT116 colon cancer cells and TK6 lymphoblast cells ( Supplementary  Information, Fig. S6b, c) . These findings suggest that not only telomere damage, but also other non-telomeric DNA damage, can activate the p53-Siah1-TRF2 pathway. However, this pathway is unlikely to be conserved in mice because the mouse Siah1a and Siah1b genes (mice have two Siah1 genes) were not induced by p53 activation, and mouse embryonic fibroblasts lacking those Siah1 genes displayed normal p53 responses, including p53-mediated cellular senescence 42 . These findings suggest another fundamental difference in telomere biology between humans and mice 43 . This study has significant implications for carcinogenesis. The negative regulation of TRF2 by p53 provides a mechanistic basis for the aberrant upregulation of TRF2 in human cancer 44, 45 . The identification of TRF2 as a novel substrate of Siah1 suggests that the regulation of telomeres and cellular senescence is a previously unknown mechanism by which Siah1 contributes to tumour suppression and reversion 46, 47 . The oncogenic activity of transgenically overexpressed Trf2 in a mouse model 45 may be attributed, at least in part, to its ability to extend cellular replicative lifespan. p53 inactivation abrogates the TRF2-ATM-p53 feedback regulation, leading to a cancer-promoting condition where dysfunctional telomeres with supraphysiological amounts of TRF2 are susceptible to chromosomal instability 45, 48 and normal senescence checkpoint is impaired. Our finding of marked p16
INK4A induction associated with the end of extended replicative lifespan (Fig. 6b) suggests that p16 INK4A inactivation could further extend the duration of this cancerpromoting condition during human carcinogenesis.
Lastly, with a growing body of evidence that telomere-initiated and/ or p53-mediated DNA damage signalling and cellular senescence have critical roles in stem cell functions and ageing processes in vivo 1,3-5,9-11 , our findings are relevant to stem cell-based regenerative medicine for ageing-related degenerative disorders. Although diminished p53 activity enhanced the self-renewing divisions in normal and cancer stem cells 4 and the efficiency of reprogramming to iPS cells 5 , it also resulted in chromosomal instability 3, 5 . An impairment of the p53-and Siah1-mediated degradation of TRF2 might in part contribute to the Fig. S5g ). These eight cases were previously described 23 and the adenoma tissues had senescent phenotypes, such as positive staining for senescence-associated β-galactosidase and increased expression of p16 INK4A and IL-8 (ref. 23) . Normalized expression levels (TRF2/β-actin) were calculated from densitometric measurement and quantitative analysis of the immunoblot data. Paired Student's t-test was performed. (d) Cellular senescence in vivo is associated with increased expression of Siah1. RNA samples were isolated from the same eight cases as in c and examined by qRT-PCR analysis for SIAH1 expression. SIAH1 mRNA levels were normalized to β2-microglobulin (β2MG) levels. Paired Student's t-test was performed. Uncropped images of blots are shown in Supplementary Information, Fig. S9 . chromosomal instability. An appropriate level of p53 activity for efficient self-renewal and pluripotency without chromosomal instability, as well as for efficient and precise differentiation of stem cells, may be influenced by the other factors involved in the TRF2-ATM-p53 positive feedback loop and the previously known negative-feedback loops 35 . Monitoring and manipulation of TRF2 expression, in combination with those of p53 activity, may improve our understanding and methodology of stem cell biology. 49 were kindly provided by M. Tainsky (Case Western Reserve University, USA). HCT116 and HCT116 p53 -/-were kindly provided by B. Vogelstein (Johns Hopkins University, USA). TK6 (p53 wild-type) and NH32 (p53-null) lymphoblast cell lines were previously described 50 . hTERT/NHF, an hTERT (human telomerase reverse transcriptase)-immortalized human fibroblast cell line, was previously described 51 . Nutlin-3a 52 was purchased from Cayman Chemical (Ann Arbor). MG132 (used at 10 μM when treating human fibroblasts) and doxorubicin were from Sigma-Aldrich. Cycloheximide was used at 100 μg ml -1 and was from Sigma-Aldrich .
METHODS
Plasmid constructs. The retroviral vectors for overexpressing full-length p53 (pQCXIN-p53) and ∆133p53 (pQCXIN-Flag-∆133p53) 23 , and the retroviral shRNA construct for p53 knockdown 53 , were previously described. The retroviral construct pLPC-Myc-TRF2 was a gift from T. de Lange (Rockefeller University, USA). To generate a retroviral expression vector of the dominant-negative mutant of SIAH1 (Flag-Siah1 ΔRING ) 27 , the human SIAH1 cDNA fragment (corresponding to amino acid residues 70-282) was PCR-amplified using a 5ʹ primer with Flagtag sequence and cloned into pBABE-puro. For a retroviral vector driving Flagtagged Siah1-Δ6 (a stable form of Siah1) 25 , the human SIAH1 cDNA fragment (corresponding to amino acid residues 6-282) was amplified and processed in the same way. To generate E. coli expression constructs of GST-Siah1 fusion proteins, the full-length SIAH1 cDNA and the Siah1 ∆RING cDNA fragment (amino acid residues 70-282, as above) were cloned into pGEX-KG (American Type Culture Collection). For Siah1 H59W , the histidine residue at position 59 in the full-length Siah1 was mutated to tryptophan using QuikChange II XL site-directed mutagenesis kit (Stratagene). The full-length TRF2 cDNA was inserted into pGEX-4T2 vector (Amersham Biosciences) to produce GST-TRF2 fusion protein. For in vitro protein synthesis, the full-length TRF2 cDNA was cloned into pEXP1-DEST vector (Invitrogen) to produce a polyhistidine tagged TRF2 (His 6 -TRF2). The cDNA fragment for GST-Siah1 fusion protein (full-length, wild-type Siah1; as in pGEX-KG above) was also cloned into pEXP1-DEST. pRK5-HA-Ub, for overexpression of HA-tagged ubiquitin, was previously described 54 . All constructs were verified by DNA sequencing. Retroviral vector transduction was performed as previously described 23 . Transient transfection of plasmid DNA was performed using Lipofectamine 2000 transfection reagent (Invitrogen). siRNA oligonucleotides. A stealth siRNA duplex oligoribonucleotide targeting SIAH1 mRNA (Siah1 2 mixture, 5ʹ-CAG GAA ACA GUU GCA UGU AGU AAC A-3ʹ and 5ʹ-GAA GCC AUG GU UCC AGA AAG UAA A-3ʹ), its scrambled control, and a standard siRNA duplex oligoribonucleotide targeting SIAH1 mRNA (Siah1 1 mixture, 5ʹ-AAU GUA ACU AUU UCC AUG UGU (dT)(dT)-3ʹ and 5ʹ-GCU GAU AGG AAC ACG CAA GCA (dT)(dT)-3ʹ) were synthesized at Invitrogen. siRNA oligonucleotides against Δ133p53 (Δ133si-1 and Δ133si-2) were described previously 23 . These siRNA oligonucleotides were transfected at the final concentration of 12 nM using Lipofectamine RNAiMAX transfection reagent (Invitrogen).
Immunoblot and immunoprecipitation.
Total protein lysates were prepared as previously described 23 . Nuclear and cytoplasmic extracts were prepared as follows. Cells were harvested, suspended in four pellet volumes of hypotonic homogenizing buffer (200 mM HEPES at pH 7.9, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% NP-40, 1 mM DTT, 10 mM NaF, 2 mM NaVO 3 and 25 mM β-glycerophosphate, supplemented with complete protease inhibitors from Roche), incubated on ice for 10 min and centrifuged at 500g for 5 min at 4 °C. The supernatants were used as cytoplasmic fractions. For nuclear extracts, the pellets were resuspended in 0.5 M NaCl, incubated on ice for 30 min and centrifuged for 30 min at 20,000g at 4 °C, followed by the collection of supernatants. For immunoblot analysis, SDS-PAGE (SDS-polyacrylamide gel electrophoresis), transfer to membranes, and incubation with antibodies, were performed as described previously 23 . Signal detection was performed using ECL detection (Amersham Biosciences) or SuperSignal West Dura Extended Duration system (Pierce Biotechnology). Immunoprecipitation followed the standard procedures as previously described 55 . The quantitative image analysis was performed using the ImageJ 1.40g software (http://rsb.info.nih.gov/ij/).
In vitro binding assay. In vitro protein synthesis of His 6 -tagged TRF2, GST and GST-Siah1 fusion protein was performed using Expressway cell-free E. coli expression system (Invitrogen), followed by the purification of His 6 -tagged TRF2 using Ni-NTA magnetic agarose beads (Qiagen), and of GST and GST-Siah1 using glutathione-Sepharose 4FF (GE Healthcare). The purified His 6 -tagged TRF2 (150 ng) bound with Ni-NTA magnetic agarose beads was incubated with 250 ng of purified GST-Siah1 or GST in 300 μl binding buffer (50 mM NaPO 4 at pH 8.0, 300 mM NaCl and 15 μM MG132, supplemented with complete protease inhibitors) for 3 h at 4 °C. The beads were washed four times with the wash buffer (50 mM NaPO 4 at pH 8.0, 300 mM NaCl, 20 mM imidazole, 0.005% Tween-20 and 15 μM MG132, supplemented with complete protease inhibitors), followed by boiling in 20 μl of SDS-PAGE sample buffer. The eluted proteins were analysed by immunoblot.
In vitro ubiquitylation assay. All recombinant proteins were expressed as GST fusion proteins in BL21 (DE3; Invitrogen) and purified using glutathione-Sepharose 4FF (GE Healthcare). After cleavage by thrombin (GE Healthcare), wild-type Siah1, Siah1
H59W and Siah1 ∆RING were purified using Benzamidine-Sepharose 4FF (GE Healthcare). The in vitro ubiquitylation assay was performed as described 56 , with slight modifications: the reaction mix contained 6.6 μl rabbit reticulocyte lysate (Promega), 1 μM ubiquitin aldehyde (Boston Biochem), 121 μM methyl ubiquitin (Boston Biochem), 1× energy solution (Boston Biochem), 150 μM ubiquitin (Boston Biochem) and 20 μM MG132 in 11.59 μl of total volume. The reaction mix was pre-incubated at 37 °C for 5 min to inhibit deubiquitylating enzymes. GST alone or GST-TRF2 as substrate (175 ng) and wild-type Siah1, Siah1 H59W or Siah1 ∆RING as enzyme (220 ng) were added to the reaction mix (final volume 20 μl) and incubated at 30 °C for 2 h. The reaction was terminated by addition of stop buffer (Boston Biochem), followed by the purification of the substrate using glutathione-Sepharose 4FF (Amersham). Immunoblot was performed using anti-GST antibody.
In vivo ubiquitylation assay. 293T cells were transfected with SIAH1 siRNA (1 or 2), or control siRNA, for 24 h and then transfected with pLPC-Myc-TRF2, pRK5-HA-Ub and pQCXIN-p53 plasmids. After 24 h, the cells were treated with 15 μM MG132 for 6 h and lysed in buffer containing 50 mM HEPES at pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 1% (v/v) glycerol, 10 μM MG132, 100 mM NaF, 1 mM NaVO 3 , 25 mM β-glycerophosphate and complete protease inhibitors.
Antibodies. The following antibodies were used: anti-TRF2 (1:1,000; 4A794, Upstate); anti-TRF2 (1:2,000; H-164, Santa Cruz Biotechnology); anti-Siah1 (1:1,000; ab2237, Abcam); anti-p53 (1:2,000; DO-1, Santa Cruz Biotechnology); anti-pS15-p53 (1:1,000; #9284, Cell Signalling Technology); anti-p21 WAF1 (1:500; EA10, Calbiochem); anti-p16 INK4A (1:1,000; G175-1239, BD Pharmingen); anti-RAP1 (1:1,000; Bethyl Laboratories, Montgomery); anti-POT1 (1:1,000; Novus Biologicals); anti-TPP1 (1:1,000; Sigma-Aldrich); anti-Siah2 (1:500; Novus Biologicals); anti-HSP90 (1:2,000; BD Biosciences); anti-Lamin A/C (1:500; Upstate); anti-Flag (1:10,000; M2, Sigma-Aldrich); anti-Myc (1:5,000; Invitrogen); anti-HA (1:1,000; 3F10, Roche); anti-GST (1:500; B14, Santa Cruz Biotechnology); anti-His (1:3,000; BMG-His-1, Roche); anti-histone H2B (1:2,000; #07-371, Upstate); anti-polyubiquitin (1:500; P4D1, Santa Cruz Biotechnology); anti-β-catenin (1:1,000; BD Biosciences); anti-α-tubulin (1:5,000; Sigma-Aldrich) and anti-β-actin (1:10,000; AC-15, Sigma-Aldrich). Anti-Δ133p53 antibody (1:5,000; MAP4) was previously described 23 . Horseradish peroxidase-conjugated goat antimouse or anti-rabbit antibodies (Santa Cruz Biotechnology) were used as secondary antibodies in immunoblot analyses.
Real-time quantitative RT-PCR. TRF2 mRNA levels were quantified using TRF2 primers purchased from Roche Applied Science (04689038001). β2-microglobulin (04688015001, Roche Applied Science) was a control for quantification. SIAH1 mRNA levels were quantified using the Taqman gene expression assay (Hs00361785_m1, Applied Biosystems). β2-microglobulin (4310886E, Applied Biosystems) was a control. The procedures and quantitative data analysis were as previously described 23 .
Examination of cellular replicative lifespan. Cell numbers were counted at each passage of siRNA-transfected cells. The number of population doubling levels (PDL) achieved between passages were determined by log 2 (number of DOI: 10.1038/ncb2123 cells obtained/number of cells inoculated) 57 . Data were means ± s.d. from three independent experiments.
Mass spectrometry. Siah1-dependent in vitro ubiquitylation reactions containing either His 6 -tagged TRF2 or GST-TRF2 as substrate were separated on a 4-12% Bis-Tris gel and stained with Colloidal Coomassie (Invitrogen). The band corresponding to unmodified tagged-TRF2 and multiple bands at higher molecular weight were cut from the gel and subjected to in-gel trypsin digestion as previously described 58 . Briefly, the cysteines were reduced with DTT (dithiothreitol) and alkylated with iodoacetamide. The protein was then digested with 13 ng μl -1 trypsin (Applied Biosystems) in 10 mM ammonium bicarbonate for 16 h at 30 °C. The peptides were extracted and dried by vacuum-evaporation using a Vacufuge (Eppendorf). The dried peptides were resuspended in water containing 2% (v/v) acetonitrile and 0.5% (v/v) acetic acid. They were then injected onto a 0.2 × 50 mm Magic C18AQ reverse phase column (Michrom Bioresources) using the Paradigm MS4 HPLC (high-performance liquid chromatography) system (Michrom Bioresources). Peptides were separated at a flow rate of 2 nl min -1 followed by online analysis by tandem mass spectrometry (MS/MS) using an LTQ ion trap mass spectrometer (Thermo Scientific) equipped with an ADVANCE CaptiveSpray ion source (Michrom Bioresources). Peptides were eluted into the mass spectrometer using a linear gradient, from 95% mobile phase A (2% acetonitrile, 0.5% acetic acid and 97.5% water) to 65% mobile phase B (10% water, 0.5% formic acid and 89.5% acetonitrile) over 20 min, followed by 95% mobile phase B over 5 min. Peptides were detected in positive ion mode using a datadependent method in which the nine most abundant ions detected in an initial survey scan were selected for MS/MS analysis. The MS/MS spectra were searched against the human IPI database (version 3.72) using TurboSEQUEST in BioWorks version 3.3.1 SP1 (ThermoElectron). The search parameters included: precursor mass tolerance: ± 1.5 amu; fragment mass tolerance: ± 0.8 amu; a static modification of + 57.02 on cysteine; a variable modification of +15.99 for methionine oxidation and a variable modification of +114.04 on lysine, for GG modification that remains after trypsin cleavage of ubiquitin modification 59 .
Statistical analyses. Statistical analysis was carried out with paired or unpaired Student's t-test as appropriate. Figure S2 Immunofluorescence staining of TRF2 and RAP1. Nuclei were counterstained with 4'-6-diamidino-2-phenylindole (DAPI). Merged images are also shown. The experimental procedures followed Yang et al. 1 (a) Early-passage (Y) and senescent (S) MRC-5 human fibroblasts (the same set as in Fig. 1a) were examined. Decreased TRF2 staining was evident in senescent cells. Scale bars, 10 mm. (b) hTERT/NHF cells transduced with p53 shRNA retroviral vector or control vector (the same set as in Fig. 2b ) were examined. Increased TRF2 staining was observed with p53 knockdown. Scale bars, 10 mm. with either of two siRNA oligonucleotides against ∆133p53 (∆133si-1 or ∆133si-2) 2 or a control oligonucleotide and examined in immunoblot analyses. (e) Inhibition of Siah-1 activity increases TRF2. The FLAG-tagged, dominant-negative mutant of Siah-1 (FLAG-Siah1-∆RING) was expressed in MDAH041 fibroblasts. b-catenin, known to be degraded by Siah-1 3 , was examined to confirm the activity of FLAG-Siah1-∆RING. (f) Overexpression of Siah-1, similar to that of p53, represses TRF2. Myc-tagged TRF2, wildtype p53 and a stabilized form of Siah-1 (FLAG-Siah1-D6) 4 were transiently transfected into 293T cells as indicated. Protein lysates were isolated 24 h post-transfection. (g) Downregulation of TRF2 in colon adenoma tissues. Immunoblot analysis of TRF2 expression in 8 pairs of colon adenoma (A) and non-adenoma (N) tissues. These 8 cases were previously described in Fujita et al. 2 The data shown in Fig. 6c were from the quantitative analysis of these results. 
